RecruitingPhase 3NCT05931276

CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes (BRAVO)

Sponsor

VA Office of Research and Development

Enrollment

2,540 participants

Start Date

May 22, 2024

Study Type

INTERVENTIONAL

Conditions

End Stage Renal Disease End-stage Kidney Disease

Summary

The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial compares different types of beta-blocker heart medications to see which ones lead to better heart outcomes in veterans on hemodialysis (kidney dialysis). You may be eligible if... - You are currently on hemodialysis - You receive one of these beta-blockers through a VA pharmacy: metoprolol, atenolol, labetalol, carvedilol, or bisoprolol You may NOT be eligible if... - You have difficulty making decisions (impaired decision-making capacity) - You have a history of asthma and are not on carvedilol - You have a known allergy to either study drug - Your provider is unwilling to write a new medication order if you are randomized - There is no surrogate available to consent on your behalf if needed Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMetoprolol Succinate

a dialyzable, beta-1 selective beta blocker

DRUGCarvedilol

a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties

Locations(8)

VA Long Beach Healthcare System, Long Beach, CA

Long Beach, California, United States

North Florida/South Georgia Veterans Health System, Gainesville, FL

Gainesville, Florida, United States

Atlanta VA Medical and Rehab Center, Decatur, GA

Decatur, Georgia, United States

Iowa City VA Health Care System, Iowa City, IA

Iowa City, Iowa, United States

VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

Boston, Massachusetts, United States

Minneapolis VA Health Care System, Minneapolis, MN

Minneapolis, Minnesota, United States

Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE

Omaha, Nebraska, United States

New Mexico VA Health Care System, Albuquerque, NM

Albuquerque, New Mexico, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05931276

Related Trials

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

NCT057158141 location

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

NCT05485961542 locations

An Extension to Assess the Effect of Expanded Dialysis on Patient Reported Symptoms Using LEVIL

NCT060322084 locations

Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial

NCT0619071721 locations

A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)

NCT073482373 locations